Cargando…

Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks

Detalles Bibliográficos
Autores principales:	Migden, Michael, Loquai, Carmen, Robert, Caroline, Baurain, Jean-François, Squittieri, Nicholas, Arntz, Ramon, Dierlamm, Jörg, Dréno, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678756/ https://www.ncbi.nlm.nih.gov/pubmed/36425794 http://dx.doi.org/10.1016/j.jdin.2022.08.027

Ejemplares similares

Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis
por: Gutzmer, Ralf, et al.
Publicado: (2021)

Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial
por: Lewis, Karl, et al.
Publicado: (2021)

Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma
por: Doan, Hung Q, et al.
Publicado: (2016)

Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis
por: Gutzmer, Ralf, et al.
Publicado: (2021)

Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma
por: Dummer, Reinhard, et al.
Publicado: (2020)

Sonidegib for the Treatment of Advanced Basal Cell Carcinoma
por: Brancaccio, Gabriella, et al.
Publicado: (2020)

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
por: Dummer, R., et al.
Publicado: (2019)

Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
por: Irvine, David A., et al.
Publicado: (2016)

Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma
por: Villani, Alessia, et al.
Publicado: (2020)

Giant basal cell carcinoma of the vulva successfully treated with Sonidegib
por: Camela, Elisa, et al.
Publicado: (2022)

Sonidegib treatment in patients with locally advanced basal cell carcinoma
por: Villani, Alessia, et al.
Publicado: (2022)

Differential pharmacology and clinical utility of sonidegib in advanced basal cell carcinoma
por: Wahid, Mohd, et al.
Publicado: (2017)

Effective systemic treatment of advanced periocular basal cell carcinoma with sonidegib
por: Rokohl, Alexander C., et al.
Publicado: (2021)

Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas
por: Villani, Alessia, et al.
Publicado: (2022)

Experience with sonidegib in patients with advanced basal cell carcinoma: case reports
por: Puig, Susana, et al.
Publicado: (2022)

Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy
por: Ross, Ashley E., et al.
Publicado: (2017)

Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas
por: Jain, Sachin, et al.
Publicado: (2017)

Sonidegib‐induced muscle spasms in the treatment of basal cell carcinoma: Strategies to adopt
por: Villani, Alessia, et al.
Publicado: (2022)

Clinical Clearance Following Improvement of Histologic Subtype of Basal Cell Carcinoma with Sonidegib
por: LEOW, Liang Joo, et al.
Publicado: (2022)

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study
por: HERMS, Florian, et al.
Publicado: (2022)

Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
por: Lear, J.T., et al.
Publicado: (2017)

A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma
por: Odom, Dawn, et al.
Publicado: (2017)

First reported case of concurrent sonidegib and radiotherapy for recurrent, advanced basal cell carcinoma
por: Wang, Kaidi, et al.
Publicado: (2021)

Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma
por: García Ruiz, Antonio J, et al.
Publicado: (2022)

The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area
por: Villani, Alessia, et al.
Publicado: (2023)

Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial
por: Lear, John T, et al.
Publicado: (2020)

Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib
por: Yoon, Jaeyoung, et al.
Publicado: (2017)

Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas
por: Tarantino, Vanessa, et al.
Publicado: (2021)

Clinical clearance of complex basal cell carcinoma in patients receiving sonidegib: A case series
por: Leow, Liang Joo, et al.
Publicado: (2021)

Optimizing the pharmacokinetics of sonidegib in small bowel syndrome and advanced basal cell carcinoma: Our solution
por: Grubbs, Hailey, et al.
Publicado: (2023)

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
por: D'Amato, C, et al.
Publicado: (2014)

Sonidegib after vismodegib discontinuation in a patient with Gorlin–Goltz syndrome and multiple basal cell carcinomas
por: Piccerillo, Alfredo, et al.
Publicado: (2021)

Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series
por: Wescott, Raquel, et al.
Publicado: (2023)

Evaluation of Hedgehog Pathway Inhibition on Nevoid Basal Cell Carcinoma Syndrome Fibroblasts and Basal Cell Carcinoma-Associated Fibroblasts: Are Vismodegib and Sonidegib Useful to Target Cancer-Prone Fibroblasts?
por: Eibenschutz, Laura, et al.
Publicado: (2021)

The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
por: Colombo, Elena, et al.
Publicado: (2023)

Tolerance of sonidegib after intolerance of vismodegib—Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome)
por: Venturi, Federico, et al.
Publicado: (2023)

Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2023)

Review of the Tumor Microenvironment in Basal and Squamous Cell Carcinoma
por: Chiang, Elizabeth, et al.
Publicado: (2023)

Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data
por: Nazzaro, Gianluca, et al.
Publicado: (2023)

Targeted Delivery of 5-Fluorouracil and Sonidegib via Surface-Modified ZIF-8 MOFs for Effective Basal Cell Carcinoma Therapy
por: Padya, Bharath Singh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jud76fhq04g09osmp1ajccjnm8